Immunohistochemical expression of Annexin A2 and Annexin A6 in a random sample group of Iraqi women with triple-negative breast cancer

Hadjir Saad Sulaiman, Hiba Ahmed Gaidan, Raghad Hanoon Zamil

Abstract


Background: Breast cancer represents the most common and the first leading cause of cancer-associated deaths in Iraqi women. It is a heterogeneous disease with different subtypes; one of these subtypes is triple-negative (basal-like) breast cancer, which is characterized by a distinctive molecular profile, aggressive clinical behavior, and the absence of targeted therapies. Annexin A2 and Annexin A6 are part of the Annexin protein family; these proteins have a suggested role in the evolution and progression of many cancer types, including breast cancer. Evaluation of the immunohistochemical expression of Annexin A2 and Annexin A6 in triple-negative subtype) in a random sample group of Iraqi women patients and correlating the results with clinicopathological parameters, including tumor grade and stage.

Methods: The current study was conducted in Baghdad /Iraq, in which forty paraffin-embedded blocks of breast tissue from women patients diagnosed with breast cancer were collected and selected to be triple-negative breast cancer. Immunohistochemical staining of Annexin A2 and Annexin A6 markers was performed for this sample with a correlation of the results with clinicopathological parameters, including tumor grade and stage.

Results: The study demonstrates a significant association between Annexin A2 and Annexin A6 expression and a significant association between Annexin A2 expression and tumor grade and stage in triple-negative breast cancer in this group of Iraqi patients.

Conclusions: This study displays the role of Annexin A2 and Annexin A6 in triple-negative breast cancer and suggests the role of Annexin A2 in the progression, metastasis, and prognosis of this special type of breast cancer by its association with advanced tumor grade and stage.

Keywords: Annexin A2; Annexin A6; triple-negative; Breast cancer


Full Text:

PDF

References


World Health Organization. International Agency for Research on Cancer. The Global Cancer Observatory , March (2021).

Toss A, Cristofanilli M. Molecular characterization and targeted therapeutic approaches in breast cancer. Breast Cancer Research, (2015); 17:60.

Millis Z, Gatalica Z, Winkler J, Vranic S, Kimbrough J, Reddy S, et al. Predictive biomarker profiling of> over 6,000 breast cancer patients shows heterogeneity in TNBC, with treatment implications. Clinical breast cancer, (2015); 15(6):473–481.

Russo J. Molecular Classification of Breast Cancer. Breast Cancer Essentials, (2021); 33–38.

Ensenyat-Mendez M, Llinàs-Arias P, Orozco J, Íñiguez-Muñoz S, Salomon M, Sesé B, et al. Current Triple-Negative Breast Cancer Subtypes: Dissecting the Most Aggressive Form of Breast Cancer. Frontiers in oncology, (2021); 16:11:681476.

Tsang J, Tse G. Molecular classification of breast cancer. Advances in anatomic pathology, (2020); 27(1):27–35.

Xi Y, Ju R, Wang Y. Roles of Annexin A protein family in autophagy regulation and therapy. Biomedicine and pharmacotherapy, (2020); 130(8):110591.

Moreau K,Ghislat G ,Hochfeld W, Renna M ,Zavodszky E, Runwal G, et al. Transcriptional regulation of Annexin A2 promotes starvation-induced autophagy. Nature communication, (2015); 6(1): 1–12.

Chen Y, Fang Y, Cheng Y, Lin C, Hsu L, Wang S, et al. Exophagy of Annexin A2 via RAB11, RAB8A, and RAB27A in IFN-gamma-stimulated lung epithelial cells. Scientific reports, (2017); 7(1):5676.

Wang C, Lin C. Annexin A2: Its Molecular Regulation and Cellular Expression in Cancer Development. Disease markers, (2014); 4: 308976.

Sharma M. Annexin A2 (ANX A2): An emerging biomarker and potential therapeutic target for aggressive cancers. International Journal of Cancer, (2019); 1; 144(9):2074-2081.

Mussunoor S, Murray G. The role of annexins in tumor development and progression. Journal of Pathology, (2008); 216:131–140.

Enrich C, Rentero C, Grewal T. Annexin A6 in the liver: from the endocytic compartment to cellular physiology. Biochimica et Biophysica Acta (BBA): Molecular Cell Research, (2017); 1864 (6): 933–946.

Koese M, Rentero C, Kota B, Hoque M, Cairns R, Wood P, et al. Annexin A6 is a scaffold for PKC alpha to promote EGFR inactivation. Oncogene, (2013); 32: 2858–2872.

Creutz C, Hira J, Gee V, Eaton J. Protection of the membrane permeability barrier by Annexins. Biochemistry, (2012); 51:9966-9983.

Alvarez-Guaita A, Vilà de Muga S, Owen D, Williamson D, Magenau A, García-Melero A, et al. Evidence for Annexin A6 dependent plasma membrane remodeling of lipid domains. British Journal of Pharmacology, (2015); 172:1677-1690.

Boye T, Maeda K, Pezeshkian W, Sønder S, Haeger S, Gerke V, et al. Annexin A4 and A6 induce membrane curvature and constriction during cell membrane repair. Nature Communication, (2017); 8:1623.

Chand P, Garg A, Singla V, Rani N. Evaluation of the Immunohistochemical Profile of Breast Cancer for Prognostics and Therapeutic Use. Nigerian Journal of Surgery, (2018); 24(2): 100–106.

Gibbs L, Mansheim K, Maji S, Nandy R, Lewis C, Vishwanatha J, et al. Clinical Significance of Annexin A2 Expression in Breast Cancer Patients. Cancers, (2021); 13(1): 2.

Gibbs L, Vishwanatha J. Prognostic impact of AnxA1 and AnxA2 gene expression in triple-negative breast cancer, (2018); 9:2697-2704.

Sakwe A, Koumangoye R, Guillory B, Ochieng J. Annexin A6 contributes to the invasiveness of breast carcinoma cells by influencing the organization and localization of functional focal adhesions. Excremental cell research, (2001); 317(6): 823–837.




DOI: http://dx.doi.org/10.62940/als.v12i1.1944

Refbacks

  • There are currently no refbacks.